Antifungal azoles for skin disorders

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 9, 2006, Pages 1235-1253

  Degreef, H ^a   Heeres, J ^b   Borgers, M ^c,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Center for Molecular Design   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Barrier Therapeutics   (Belgium)

Author keywords

Azoles; Candidosis; Dermatophytes; Onychomycosis; Pityriasis versicolor; Seborrhoeic dermatitis; Tinea

Indexed keywords

ALLYLAMINE DERIVATIVE; AMOROLFINE; ANTIFUNGAL AGENT; BAY W 6341; BIFONAZOLE; CICLOPIROX; CICLOPIROXOLAMINE; CLOTRIMAZOLE; CYTOCHROME P450; ECONAZOLE; ERTAZO; FLUCONAZOLE; GRISEOFULVIN; HYPHANOX; IMIDAZOLE; ISOCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LAURIAD; MICONAZOLE; MORPHOLINE DERIVATIVE; NAFTIFINE; OXICONAZOLE; PRAMICONAZOLE; PYRROLE DERIVATIVE; SERTACONAZOLE; STEROL 14ALPHA DEMETHYLASE; TERBINAFINE; TIOCONAZOLE; TRIAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VUSION; XOLEGEL;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE IRRITATION; BINDING AFFINITY; BINDING SITE; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DERMATOMYCOSIS; DIAPER DERMATITIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ONYCHOMYCOSIS; OROPHARYNX CANDIDIASIS; PATENT; REVIEW; RISK BENEFIT ANALYSIS; SEBORRHEIC DERMATITIS; SKIN IRRITATION; STRUCTURE ACTIVITY RELATION; SURGICAL TECHNIQUE; TINEA CAPITIS; TINEA PEDIS; TINEA VERSICOLOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33748701228     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.9.1235     Document Type: Review

References (93)

1. WEITZMAN I, SUMMERBELL RC: The dermatophytes. Clin. Microbiol. Rev. (1995) 8:240-259.
2. MATSUMOTO T: Fungal diseases in dermatology. In: Principle and Practice of Clinical Mycology. Kibber CC, Mackenzie DWR, Odds FC (Eds). John Willey & Sons Ltd, England (1996):103-129.
3. FAERGEMANN J: Atopic dermatitis and fungi. Clin. Microbiol. Rev (2002) 15:545-563.
4. BORGERS M: Ultrastructural correlates of antimycotic treatment. In: Current Topics in Medical Mycology. McGinnis M (Ed.). Springer, Berlin, (1988) 2:1-39.
5. SLOBODA RD, VAN BLARICOM C, CREASEY WA, ROSENBAUM JL, MALAWISTA SE: Griseofulvin: association with tubulin and inhibition of in vitro microtubule assembly. Biochem. Biophys. Res. Commun. (1982) 105:882-888.
6. HAZEN KC: Fungicidal activity of terbinafine and itraconazole in vitro. J. Am. Acad. Dermatol. (1998) 38:S37-S41.
7. RYDER NV, MIETH: Allylamine antifungal drugs. In: Current Topics in Medical Mycology. Borgers, Hay, Rinaldi (Eds). Springer, New York (1992) 4:158-188.
8. HARTMAN PG, POLAK A: Preclinical data of amorolfine. In: Cutaneous Antifungal Agents. Rippon JW, Frorntling RA (Eds). Marcel Dekker, New York (1993):13-26.
9. VANDEN BOSSCHE H: Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. In: Current Topics in Medical Mycology. McGinnis MR (Ed.) Springer, New York (1985) 1:313-359.
10. KOBAYASHI D, KONDO K, UEHARA N et al: Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob. Agents Chemother. (2002) 45:3113-3117.
11. WOOLLEY DW: Some biological effects produced by benzimidazole and their reversal by purines. J. Biol. Chem. (1944) 152:225-232.
12. DEGREEF H, VAN DE KERCKHOVE M, GEVERS D, VAN CUTSEM J, VANDEN BH, BORGERS M: Ketoconazole (R 41 400) in the treatment of dermatophyte infections: a clinical, mycological, and morphological study. Int. J. Dermatol. (1981) 20(10):662-667.
13. PALACIN C, TARRAGE C, ORTIZ JA: Sertaconazole pharmacology of a gynecological antifungal agent. Int. J. Gynaecol Obstet. (2000) 71(l):837-846.
14. CARRILLO-MUNOZ AJ, GAGLIETTA A, PALACIN C et al.: In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and scopulariopsis brevicaulis. Chemotherapy (2004) 50:308-313.
15. MAERTENS JA: History of the development of azole derivatives. Clin. Microbiol. Infec. (2004) 10(1): 1-10.
16. DE NOLLIN S, VAN BELLE H, GOOSSENS F, THONE F, BORGERS M: Cytochemical and biochemical studies of yeast after in vitro exposure to miconazole. Antimicrob. Agents Chemother. (1977) 11:500-513.
17. FRANCOIS IE, CAMMUE B, BORGERS M, AUSMA J, DISPERSYN GD, THEVISSEN K: Azoles: mode of antifungal action and resistance development. Effect of miconazole on endogenous reactive oxygen species production in Candida albicans. Anti-Infective Agents in Med. Chem. (2006) 5:3-13.
18. DUMITRI R, HORNBY JM, NICKERSON KW. Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs. Antimicrob. Agents Chemother. (2004) 48(7):2350-2354.
19. SUD IJ, FEINGOLD DS: Action of antifungal imidazoles on Staphylococcus aureus. Antimicrob. Agents Chemother. (1982) 22:470-474.
20. ROSEN T, SCHELL BY, ORENGO I: Anti-inflammatory activity of antifungal preparations. Int. J. Dermatol. (1997) 36:788-794.
21. FAERGEMANN J: Management of seborrhoeic dermatitis and pityriasis versicolor. Am. J. Clin. Dermatol. (2000) 1:75-80.
22. SANGLARD D, BILLE J: Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections. In: Candida and candidiasis. Calderone RA (Ed.). ASM Press, Washington, DC (2002) 349-383.
23. NIIMI M, NIIMI K, TAKANO Y et al.; regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J. Antimicrob. Chemother. (2004) 54(6):999-1006.
24. SANGUINETTI M, POSTERARO B, FIORI B, RANNO S, TORELLI R, FADDA G: Mechanisms of azole resistance in clinical isolates of Canaida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. (2005) 49(2):668-679.
25. DE BRABANDER M, AERTS F, VAN CUTSEM J, VANDEN BH, BORGERS M: The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans. Sabouraudia (1980) 18:197-210.
26. CETINKAYA Z, KIRAZ N, KARACA S et al.: Antifungal susceptibilities of dermatophytic agents isolated from clinical specimens. Eur. J. Dermatol. (2005) 5:258-261.
27. RICHARDSON K: The discovery of fluconazole. In: Cutaneous Antifungal Agents Rippon JW, Fromtling RA (Eds). Marcel Dekker, New York (1993) 171-185.
28. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS (NCCLS): Reference method for broth dilution antifungal susceptibility testing of conidium forming filamentous fungi. proposed standard, NCCLS document M38-P: Wayne PA (1997) 18(13).
29. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS (NCCLS): Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard (2nd Ed) NCCLS: Wayne PA (2002) 17(9).
30. BOLOGNIA JL, JORRIZZO JL, RAFINI PR: In: Dermatology. Mosby (Ed.) Elsevier Limited, London. (2003) 20-24.
31. DEGREEF H: Itraconazole in the treatment of tinea capitis. Cutis (1996) 58(1):90-93.
32. DECREEF H, DE DONCKER P: In: Fighting fungal infections around the globe. (Ed.) Wells Publ. Medical Holdings, England. (2000) 85-95.
33. GINTER-HANSELMEYER G, SMOLLE J, GUPTA A: Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort. Pediatr Dermatol. (2005) 22(4):499-502.
34. FLEECE D, GANCHAN JP, ARONOFF SC: Griseoftilvin versus terbinafine in the treatment of tinea capitis. Pediatrics (2004) 144:1312-1315.
35. SCHER RK: Onychmycosis: a significant medical disorder. J. Am. Acad. Dermatol. (1996) 35(3 Pt 2):S2-S5.
36. BOLOGNIA JL, JORIZZO JL, RAFINI PR: In: Dermatology. (Ed.) Mosby, Elsevier Limited, London. (2003) 1184
37. GUPTA AK, RYDER JE: The use of oral antifungal agents to treat onychomycosis. Dermatolog. Clin. (2003) 21:469-479.
38. DOMPMARTIN D, DOMPMARTIN A, DELUOL AM, GROSSHOUS E, COULAUD AV: Onychomycoses and AIDS. Clinical and Laboratory findings in 62 patients. Int. J. Dermatol. (1990) 29:337-339.
39. FARRE B, GHANNORIM MA, RYDER NS: Biochemical characterization of terbinafine-resistant Trichophytes rubrum isolates. Med. Mycol. (2004) 42:525-529.
40. DANIER CR: Traditional management of onychomycosis. J. Am. Acad. Dermatol. (1996) 35:521-525.
41. BARAN R, HAY RJ: Partial fungical avulsion of the nail in onychomycosis. Clin. Exp. Dermatol. (1985) 10:413-418.
42. NOLTING S: Non-traumatic removal of the nail and simultaneous treatment of onychomycosis. Wien. Med. Wocbenschr. (1989) 139:354-355.
43. HAY RJ, MACKIE RM, CLAYTON YM: Tioconazole nail solution: an open study of its efficacy in onychomycos. Clin. Exp. Dermatol. (1985) 10:111-115.
44. HAY RJ, ROBERTS DT, DOHERTY VR, RICHARDSON MD, MIDGLEY G: The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin. Exp. Dermatol. (1988) 13:164-167.
45. GUPTA AK, TOMAS E: New antifungal agents. Dermatol. Clin. (2003) 21:565-576.
46. HARIA M, BRYSON HM: Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs (1995) 49:103-120.
47. DEGREEF H, DE DONCKER P: Current therapy of dermotophytosis: J. Am. Acad. Dermatol. (1993) 31;S25-S30.
48. WILLEMSEN M, DE DONCKER P, WILLEMS J et al.: Post treatment itraconazole levels in the nail. New implications for treatment in onychomycosis. J Am. Acad. Dermatol. (1992) 26:731-735.
49. CAUWENBERGH G, DEGREEF H, HEYKANTS J et al.: Pharmacokinetic profile of orally administered itraconazole in human skin. J. Am. Acad. Dermatol. (1988) 18(2 Pt. 1):263-268.
50. SIGURGEIRSON B, OLAFSSON JH, STEINSSON JB et al.: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch. Dermatol. (2002) 138:353-357.
51. BARAN R: Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost effective treatment for onychomycosis. Br. J. Dermatol. (2001) 145(60):15-19.
52. LECHA M: Amorolfine and itraconazole combinations for severe toenail onychomycosis: results of an open randomized trial in Spain. Br. J. Dermatol. (2001) 145(Suppl. 60):21-26.
53. AVNER S, NIR N, HENRI T: Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J. Dermatolog. Treat. (2005) 16:327-330.
54. BARAN R, KAOUKHOV A: Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J. Eur. Acad. Dermatol. (2005) 19:21-29.
55. HUI X, CHAN TC, BARBADILLIO S et al: Enhanced econazole penetration into human nail by 2-n-monyl-1,3-dioxatane. J. Pharm. Sci. (2003) 92:142-148.
56. GUPTA AK, LYNDE CW, KONNIKOV N: Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. (2001) 44:485-491.
57. CARDOT JM, CHAUMONT C, DUBRAY C et al.: Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy and female subjects. Br. J. Clin. Pharmacol. (2004) 58:345-348.
58. MOHAMMED FA, KHEDR H: Preparation and in vivolin vitro evaluation of the buccal bio adhesive properties of slow-release tablets containing miconazole nitrate. Durg. Dev. Ind. Pharm. (2003) 29:321-327.
59. SPRAKER MK, GISOLDI EM, SIEGFRIED EC et al.: Topical miconazole nitrate ointment in the treatment of diaper dermatitis complicated by Candidiasis. Cutis (2006) 77:113-120.
60. PIÉRARD-FRANCHIMONT C, ARRESE JE, PIÉRARD GE: How to manage seborrheic dermatitis. Rev. Med. Liège (2003) 58:67-69.
61. GUPTA AK, NICOL K, BATRA R: Role of antifungal agents in the treatment of seborrheic dermatitis. Am. J. Clin. Dermatol. (2004) 5(6):417-422.
62. FAERGEMANN J: Management of seborrheic dermatitis and pityriasis versicolor. Am. J. Clin. Dermatol. (2000) 1(2):75-80.
63. PIÉRARD-FRANCHIMONT C, VROOME V, CAUWENBERGH G, PIÉRARD GE: Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. Skin Pharmacol. Physiol. (2005) 18:98-102.
64. BEGER B, HIGHTON A, BARRANCO C, LEGENDRE R: A double-blind, randomized, vehicle-controlled, parallelgroup, multicenter study to assess the efficacy and safety of a topical gel product containing ketoconazole SP 2% in the treatment of seborrheic dermatitis. J. Am. Acad. Dermatol. (2005) 52:122 (Abstract).
65. BEGER B, HIGHTON A, LEGENDRE R: The irritation potential of topical formulations containing ketoconazole 2% and desonide 0.05% alone and in combination. J. Am. Acad. Dermatol. (2005) 52:61 (abstract).
66. UCHIDA K, NISHIYAMA Y, TANAKA T, YAMAGUCHI H: In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. Int. J. Antimicrob. Agents (2003) 2l:234-238.
67. KUZAHARA N, KODAMA H, YOSHIDA M, MIYAZAKI T, YAMAGUCHI H: In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob. Agents Chemother. (1998) 42:967-970.
68. UCHIDA K, NISHIYAMA Y, YAMAGUCHI H: In vitro activity of luliconazole (NND-502), a novel imidazole antifungal agent. J. Infect. Chemother. (2004) 10:216-219.
69. NIWANO Y, KUZAHARA N, GOTO Y et al.: Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. Int. J. Antimicrob. Agents (1999) 12:221-228.
70. NIWANO Y, KOGA H, KODAMA H, KANAI K, MIYAZAKI T, YAMAGUCHI H: Inhibition of sterol 14α-demerthylation of Candida albicans with NND-502, a novel optically active imidazole antimycotic agent. Med Mycology (1999) 37:351-355.
71. ROSSELLO A, BERTINI S, LAPUCCI A et al.: Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J. Med. Chem. (2002) 45:4903-4912.
72. SILVESTRY R, ARTICO M, LA REGINA G et al.: Imidazole analogues of fluoxetine, a novel class of anti-Candida agents. J. Med. Chem. (2004) 47:3924-3926.
73. SAHA AK, LIU L, MARICHAL P, ODDS F: Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulphonamides towards optimization of in vitro activity. Bioorg. Med. Chem. Lett. (2000) 10:2735-2739.
74. FOSTEL JM, LARTEY PA. Emerging novel antifungal agents. Drug Discov. Today (2000) 5:25-32.
75. OHWADA J, TSUKAZAKI M, HAYASE T et al.: Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. Bioorg. Med. Chem. Lett. (2003) 13:191-196.
76. KOBAYASHI K, HORII I: Comparative toxicological assessment of a water-soluble azole administered both orally and by intravenous continuous infusion in cynomolgus monkeys. J. Tox. Sci. (2002) 27:107-122.
77. GUPTA AK, RYDER JE: The use of oral antifungal agents to treat onychomycosis. Dermatolog. Clin. (2003) 21:469-479.
78. GUPTA AK, THOMAS E: New antifungal agents. Dermatol. Clin. (2003) 21:565-576.
79. FERNANDEZ-TORRES B, CARRILLO AJ, MARTIN E et al.: In vitro activities of 10 antifungal drugs against 508 dermarophyte strains. Antimicrob. Agents Chemother. (2001) 45:2524-2528.
80. GHANNOUM MA, CHATURVEDI V, ESPINEL-INGROFF A et al.: Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin. Microb. (2004) 42:2977-2979.
81. FAVRE B, HOFBAUWER B, HILDERING KS, RYDER NS: Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J. Clin. Microb. (2003) 41:4817-4819.
82. BARCHIESI F, ARZENI D, CAMILETTI V et al.: In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin. Microb. (2001) 39:4208-4209.
83. GUPTA AK, KOHLI Y, BATRA R: In vitro activity of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med. Mycol. (2005) 43:179-185.
84. VAN LOO D: Voriconazole: an evaluation of activity and use. J. Infect. Dis. Pharmacother. (2003) 6:15-37.
85. KAMAI Y, HARASAKI T, FUKUOKA T et al.: In vitro and in vivo activities of CS-758 (R-120758), a new trizole antifungal agent. Antimicrob. Agents Chemother. (2002) 46:367-370.
86. KONOSU T, FUKUOKA T: CS-758, a new triazole antifungal agent: synthesis, structure-activity relationships and antifungal activity. Ann. Rep. Sankyo Res. Lab. (2001) 53:81-92.
87. KAMAI Y: CS-758, a new triazole agent: In vivo antifungal activity against experimental Candidiasis, Aspergillosis, and Cryptococcosis. Ann. Rep. Sankyo Res. Lab. (2004) 56:1-10.
88. MEERPOEL L, BACKX LJJ, VAN DER VEKEN LJ et al.: Synthesis and in vitro and in vivo structure-activity relationship of novel antifungal triazoles for dermatology. J. Med. Chem. (2005) 48:2184-2193.
89. ODDS F, AUSMA J, VAN GERVEN F et al.: In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob. Agents Chemother. (2004) 48:388-391.
90. FAERGEMANN J, AUSMA J, BORGERS M: The in vitro activity of R126638 and ketoconazole against Malassezia species. Acta. Derm. Venereol. (2006) In press.
91. FAERGEMANN J, AUSMA J, WOUTERS L, BORGERS M: An open label trial to evaluate the effect of oral treatment with R126638 in pityriasis versicolor. JEADV(2005) 19(2):1-91 (Abstract).
92. PIERARD-FRANCHIMONT C, AUSMA J, WOUTERS L et al.: The activity of R126638, a new triazole antifungal, as assessed by corneofungimetry. Skin Pharmacol. Physiol. (2006) 19:50-56.
93. AUSMA J, WOUTERS L, VANDEPLASSCHE L, BORGERS M, DECROIX J: Effect of a new azole R126638 in tinea pedis: pilot trial of a 3 or 5 days treatment. JEADV (2005) 19(2):1-87 (Abstract).